Investigational drug · Phase 3
Zodasiran
Also called: AROANG3, VSA003
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Homozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia (HoFH).
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Zodasiran"
First trial start
2024
Nov 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zodasiran", any sponsor or status.
Conditions studied
As listed on its trial records.
- Homozygous Familial Hypercholesterolemia
- Homozygous Familial Hypercholesterolemia (HoFH)
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Zodasiran" as an intervention, largest first.
- A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)Pivotal-lookingActive, not recruiting
Arrowhead PharmaceuticalsIndustry
NCT07037771 · 70 participants · Start Jun 17, 2025 · Primary completion Aug 20, 2027
Drug: zodasiran Injection; Placebo · For: Homozygous Familial Hypercholesterolemia
Sites: Park Ridge, Illinois; New York, New York; Cincinnati, Ohio · 43 sites in all
- A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH PatientsPivotal-lookingActive, not recruiting
Visirna Therapeutics HK LimitedIndustry
NCT06712771 · 46 participants · Start Nov 27, 2024 · Primary completion Dec 31, 2025
Drug: VSA003; Placebo · For: Homozygous Familial Hypercholesterolemia (HoFH)
Sites: Beijing, China
- Study of Zodasiran in Adolescent Participants With Homozygous Familial HypercholesterolemiaPivotal-lookingRecruiting
Arrowhead PharmaceuticalsIndustry
NCT07473843 · 10 participants (planned) · Start Oct 2026 · Primary completion Jul 2028
Drug: Zodasiran · For: Homozygous Familial Hypercholesterolemia
Sites: St Louis, Missouri; Viborg, Denmark; Warsaw, Poland
Newest research
PubMed records naming it or its code names, newest first.
- Effectiveness and safety of target-specific RNA-based lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
Widjaja JS, Adji AS, Baraja A, et al. · Eur J Pharmacol 2026
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 European Society of Cardiology Conference.
Abdul Jabbar AB, Zulfiqar K, Malik SAR, et al. · Curr Atheroscler Rep 2026
- Zodasiran in mixed hyperlipidaemia: durable lipid lowering, cardiovascular benefit unresolved.
Ahmadizar F, Hollander M · Eur J Prev Cardiol 2026
- Longer-Term Efficacy and Safety of Zodasiran in Patients with Mixed Hyperlipidaemia.
Rosenson RS, Gaudet D, Ballantyne CM, et al. · Eur J Prev Cardiol 2026
- Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels.
Hegele RA · Expert Opin Ther Targets 2026
- Effect of angiopoietin-like protein 3 inhibitors on lipid profile and other biomarkers: a meta-analysis of randomized controlled trials.
Xie S, Galimberti F, Olmastroni E, et al. · Eur J Prev Cardiol 2026
Also in development for Homozygous Familial Hypercholesterolemia
- SHR-1918Phase 37 trials
Beijing Suncadia Pharmaceuticals Co., Ltd · Homozygous Familial Hypercholesterolemia, Hyperlipidemia, Hypercholesterolemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.